Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

European Commission Approves Kisqali® for HR+/HER2- Early Breast Cancer at High Risk of Recurrence

European Commission Approves TEVIMBRA® for First-Line Treatment of ESCC and G/GEJ Adenocarcinoma

ICPO Theranostics Virtual Summit 2024: Advancing a New Era in Precision Oncology

Home
/
update
/
details

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

NextEdge Admin

28 Nov 2024

2 min 32 sec

The Thane-based SunAct Cancer Institute has partnered with Malaysian pioneer Abgentil Biomedical SDN BHD to bring cutting-edge CAR-T, TCR, and TIL therapies for solid tumors to India at affordable costs. The agreement was recently signed at SunAct’s premises by founder and renowned oncologist Dr. Vijay Patil and Abgentil's managing director, Loh Hui Pin.

Dr. Patil expressed excitement about introducing these advanced cancer treatments, emphasizing their potential to bring hope to patients with solid tumors, a majority of India’s cancer diagnoses. He highlighted the critical need for innovative therapies like CAR-T, TCR, and TIL for patients in advanced stages, where conventional treatments often fail. These therapies have shown remarkable efficacy, with TIL gaining FDA approval for melanoma and TCR recently authorized for sarcoma post-chemotherapy failure. However, accessibility to such treatments remains a challenge in India—a gap SunAct aims to bridge.

Loh Hui Pin praised Dr. Patil and his team’s commitment to eradicating cancer, expressing confidence in the partnership’s potential to transform care for Indian patients.

SunAct is the first in India to offer CAR-T and TCR for solid tumors and plans to expand its services across the country. New centers in Mumbai, Pune, Delhi/NCR, and Bengaluru are set to launch over the next five years, making revolutionary therapies accessible nationwide.

Led by Dr. Vijay Patil, a distinguished oncologist with over 660 research papers and experience at Tata Memorial and P.D. Hinduja hospitals, SunAct is dedicated to delivering cutting-edge treatments globally at a fraction of the cost, offering new hope in the battle against advanced malignancies.